Cost-Consequence Analysis of Three Different Diagnostic Strategies in the First- and Second-Line Treatment of Locally Advanced or Metastatic Non-Small-Cell Lung Cancer. (2018). Farmeconomia. Health Economics and Therapeutic Pathways, 19(1). https://doi.org/10.7175/fe.v19i1.1354